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RTS,S/AS01E immunization increases
antibody responses to vaccine-unrelated
Plasmodium falciparum antigens associated
with protection against clinical malaria in
African children: a case-control study
Carlota Dobaño1,2* , Itziar Ubillos1, Chenjerai Jairoce2, Ben Gyan3,4, Marta Vidal1, Alfons Jiménez1,5,
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Abstract
Background: Vaccination and naturally acquired immunity against microbial pathogens may have complex
interactions that influence disease outcomes. To date, only vaccine-specific immune responses have routinely been
investigated in malaria vaccine trials conducted in endemic areas. We hypothesized that RTS,S/A01E immunization
affects acquisition of antibodies to Plasmodium falciparum antigens not included in the vaccine and that such
responses have an impact on overall malaria protective immunity.
Methods: We evaluated IgM and IgG responses to 38 P. falciparum proteins putatively involved in naturally
acquired immunity to malaria in 195 young children participating in a case-control study nested within the African
phase 3 clinical trial of RTS,S/AS01E (MAL055 NCT00866619) in two sites of different transmission intensity
(Kintampo high and Manhiça moderate/low). We measured antibody levels by quantitative suspension array
technology and applied regression models, multimarker analysis, and machine learning techniques to analyze
factors affecting their levels and correlates of protection.
Results: RTS,S/AS01E immunization decreased antibody responses to parasite antigens considered as markers of
exposure (MSP142, AMA1) and levels correlated with risk of clinical malaria over 1-year follow-up. In addition, we show
for the first time that RTS,S vaccination increased IgG levels to a specific group of pre-erythrocytic and blood-stage
antigens (MSP5, MSP1 block 2, RH4.2, EBA140, and SSP2/TRAP) which levels correlated with protection against clinical
malaria (odds ratio [95% confidence interval] 0.53 [0.3–0.93], p = 0.03, for MSP1; 0.52 [0.26–0.98], p = 0.05, for SSP2) in
multivariable logistic regression analyses.
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Conclusions: Increased antibody responses to specific P. falciparum antigens in subjects immunized with this partially
efficacious vaccine upon natural infection may contribute to overall protective immunity against malaria. Inclusion of
such antigens in multivalent constructs could result in more efficacious second-generation multistage vaccines.
Keywords: Malaria, Plasmodium falciparum, Vaccine, RTS,S, Antibody, Pre-erythrocytic antigens, Blood-stage antigens,
Naturally acquired immunity, Protection, Maternal antibodies
Background
Immunity against infectious diseases can be acquired
by natural exposure to the microbe, or through inter-
vention by vaccination, although in neither case is
immunity necessarily sterile. Naturally acquired and
experimentally induced immunity to infectious dis-
eases are not necessarily mediated by the same host
mechanisms, particularly in the case of pathogens that
may have multiple and complex life cycle stages and
where several potential immune effectors such as
antibody vs cellular may act on distinct phases of
infection. The way naturally acquired immunity (NAI)
interacts with active immunization in clearing mi-
crobes in vaccinated subjects is multifaceted and not
well understood. First, pre-existing immunity, as a re-
sult of prior exposure to infection and/or passively
transferred maternal IgGs in the case of neonates and
infants [1], may have an impact on response to vac-
cines and induction of protective efficacy. Second,
immune responses induced by continuous exposure to
pathogens before, during, and right after vaccination
may also affect the type and magnitude of vaccine-in-
duced immune responses and impact protective immunity
against the disease and thus alter overall vaccine efficacy.
Third, vaccination with partially or fully effective vaccines
inducing moderate or strong immunity could decrease
microbe exposure that is required for the induction and/
or maintenance of NAI and this may result in a “rebound”
in the incidence of disease if the vaccine is moderately effi-
cacious and short-lived.
In the case of malaria caused by Plasmodium falcip-
arum, in areas of heavy and continuous transmission,
NAI is acquired with age and exposure and conse-
quently the burden of disease is concentrated in chil-
dren [2]. NAI is mediated mainly by IgG antibodies to
antigens of the parasite asexual blood stage (BS) [3],
but the specific epitope targets have not been un-
equivocally defined. The most advanced malaria vaccine
globally, RTS,S/AS01E, has been tested in African sub-
jects in phase 2 and 3 trials, showing consistent though
moderate and waning efficacy against clinical malaria
(range 55.8% in children to 31.3% in infants after 1 year of
follow-up) [4, 5]. RTS,S elicits strong IgG antibodies to the
circumsporozoite protein (CSP), the predominant protein
of the P. falciparum pre-erythrocytic (PE) stage sporozoite,
a response that has been implicated in vaccine-induced
protection against malaria [6, 7], albeit inconsistently.
Neither the effect that natural exposure and/or pre-
existing immunity could have on RTS,S efficacy and
longevity nor how vaccination affects NAI has been in-
vestigated in sufficient depth.
Based on clinical and immunogenicity data from previ-
ous phase 2b trials in Manhiça, Mozambique [8, 9], we
proposed a model of development of protection to RTS,S
that was dependent on the intricate interaction between
vaccination and NAI, which might influence duration of
vaccine efficacy [10]. We postulated that duration of
vaccine efficacy depends on two distinct, but related,
mechanisms: (1) initial partial PE protection via induction
of vaccine-specific immune responses, which reduces the
release of merozoites from the liver into the bloodstream,
and (2) long-term protection resulting from enhancement
of BS immunity facilitated through subclinical BS infec-
tion due to partial RTS,S protection (the “leaky vaccine”
hypothesis). This represents a fourth, unexplored mechan-
ism of vaccine interaction with NAI whereby reduced
microbial burden resulting from partial vaccine efficacy
may enhance NAI through a low-dose stimulus to the im-
mune system [11]. Our previous analyses of Mozambican
phase 2b trial samples measuring antibodies to a panel of
P. falciparum antigens revealed that RTS,S vaccinees had
similar or significantly lower IgG responses than compara-
tor vaccines at 6months after vaccination, particularly in
younger children < 2 years of age [12]. Thus, there was no
evidence of an enhancement of BS immunity through
RTS,S vaccination. Rather, measured antibodies repre-
sented markers of exposure and reduction of antibody
breadth and magnitude reflected vaccine efficacy [13].
In this study, using multiplex quantitative suspension
array assays, we evaluated within the pediatric multicen-
ter African RTS,S phase 3 clinical trial the impact of
vaccination on NAI using an expanded panel of antigens
that are putatively associated with malaria immunity and
exposure. As NAI is dependent upon age and exposure,
and may significantly affect vaccine efficacy, we included
infant and children cohorts from two sites of different
malaria transmission intensity (MTI). We investigated
whether antibody responses 1 month post-immunization
were modified by RTS,S and whether these responses
contributed to malaria protective immunity.
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Methods
Design
This study was carried out in two of the seven sites
included in the multicenter immunology study MAL067,
ancillary to the phase 3 randomized clinical trial
MAL055 (NCT00866619): Kintampo in Ghana (moder-
ate-high MTI) and Manhiça in Mozambique (low MTI)
[6]. Briefly, our study included 109 infants aged 6–12
weeks and 86 children aged 5–17months from the phase
3 trial who were randomly assigned to receive 3 doses of
either the RTS,S/AS01E vaccine or a comparator vaccine
(the meningococcal C conjugate in infants or rabies vac-
cines in children) during month (M) 0, 1, and 2. Subjects
were followed up by passive case detection (PCD) start-
ing at M0 and during the subsequent study months. For
correlates of protection analyses in our study, we used a
follow-up time of 12 months, when subjects were cen-
sored, and starting 14 days after sample collection at M3
(approximately 44 days after the third dose at M2). Sub-
jects with ≥ 150 μL plasma/serum samples available at
M0 (baseline) and M3 were selected. We included 129
RTS,S/AS01E- and 66 comparator-vaccinated children
and infants from both sites. For the correlates of malaria
protection/risk analysis, 78 children and infants were
randomly selected from Kintampo, and 117 participants
were selected from Manhiça according to a prior case-
control study of cellular markers [14], and all were
analyzed in a case-control design.
Antibody assays
Quantitative suspension array technology (qSAT) apply-
ing the xMAP™ technology (Luminex Corp., Texas) was
used to measure antibody responses to 38 P. falciparum
antigens including three CSP constructs (Additional file 1:
Table S1). Antigens were selected on the basis of profil-
ing BS immunity, but also for the effect of vaccination
on PE immune responses to sporozoite (SSP2/TRAP
and CelTOS) and liver stages (LSA1). Although some of
the BS antigens have been characterized as markers of
exposure, such as AMA1 and MSP1 [15], antigen selec-
tion was primarily directed toward prominent targets of
immunity, vaccine candidates, or prior association with
protection in seroepidemiological studies or animal models.
Additionally, several antigens were specifically included
with said characteristics and limited polymorphism (e.g.,
RH2, RH4, RH5, and EBA140). VAR2CSA, a pregnancy-re-
stricted variant of P. falciparum erythrocyte membrane
proteins, was included as a representation of maternally
derived antibodies.
qSAT assays contained bovine serum albumin (BSA) and
glutathione S-transferase (GST)-coupled beads for back-
ground determination and as a control for signal from non-
specific binding of P. falciparum GST fusion proteins,
respectively. P. falciparum proteins were covalently coupled
directly to MagPlex beads and blocked with BSA. qSAT as-
says were previously standardized and optimized to control
for sources of variability [16–18]. Briefly, antigen-
coupled multiplex beads were mixed with 50 μL of test
sample, negative or positive control [8, 19], at multiple
dilutions (see Additional file 1). After incubation and
washing, biotinylated secondary antibodies were added.
Following streptavidin-R-phycoerythrin incubations, sam-
ples were acquired with a Luminex 100/200 analyzer and
antibody levels measured as median fluorescence intensity
(MFI). Data pre-processing is detailed in Additional file 1.
Data analysis
Comparisons of crude Ig levels (log10 MFI) across anti-
gens and isotypes were done through boxplots with geo-
metric means, medians, and interquartile ranges (IQR),
by t tests, and p values adjusted for multiple compari-
sons by the Holm approach [20]. Analyses included ei-
ther all subjects or separately by visit and by vaccination,
and in some cases stratifying by site, by age, and by age
group within a site. To evaluate factors affecting M3 Ig
levels to each antigen, we fitted first univariable and next
multivariable linear regression models (coefficient, 95%
confidence interval [CI], p values) including the follow-
ing predictors: vaccination, sex, malaria transmission
season at M3, having clinical malaria episodes between
M0 and M3, and baseline variables like age cohort, anti-
body levels (using the same antigen/Ig as the outcome
variable at M3), hemoglobin (Hb) concentrations,
weight-for-age Z-score (WAZ), and height-for-age Z-
score (HAZ). Models were also fitted separately at pre-
vaccination (M0). Malaria transmission season was de-
fined as high between April and October for Kintampo
and November and April for Manhiça; the remaining
months were defined as low transmission season. Linearity
of the associations with continuous covariates was evalu-
ated through penalized splines in generalized additive
models (GAM); variables were modeled as linear. A com-
bination of backward and forward stepwise algorithm was
used in multivariable models.
Analysis of antibody correlates of protection against
clinical malaria (fever > 37.5 °C with any parasitemia in
the 12months after M3.5) was based on a case-control de-
sign. Logistic regression models (odds ratio [OR], 95% CI,
p values) were fitted first univariable and next multivari-
able to obtain the effect of different predictors in the odds
of having malaria. Main predictors included levels (log10
MFI) of antibodies at M3 and change in antibody levels
from M0 to M3. The change in antibody levels from M0
to M3 was calculated as the difference between log10 MFI
levels at M3 and log10 MFI levels at M0 (log10 fold change
[FC]) for each antibody-antigen pair. The impact of the
other covariates (same as above) on the association be-
tween antibody responses and malaria risk/protection was
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also assessed. The linearity of the log10-transformed anti-
body levels was evaluated when the outcome was case-
control. Multivariable models were obtained through the
stepwise algorithm, R package MASS and function ste-
pAIC. Both backwards and forward methods were com-
bined to obtain the model with the minimum Akaike
information criterion (AIC). All potential variables were
proposed in the first step of the model, not only the
significant ones.
Finally, we performed multimarker analysis by princi-
pal component analysis (PCA), correlation matrices, and
machine learning partial least squares discriminant ana-
lysis (PLS-DA) using the R packages FactoMineR [21],
Corrplot [22], and DiscriMiner [23], respectively. PLS-
DA is a supervised method useful when there are many
colinear variables. It is similar to PCA, but in addition it
also takes into account a categorical response variable
(clinical malaria or non-malaria in our case). Based on
this, it creates new components with different loadings
of the explanatory variables (antibody levels to the differ-
ent antigens in our case) that better explain the response
variable. For the PCA analysis, we included the log10-
transformed levels of all antigen-isotype pairs at M3 to
generate the principal components. We selected the first
three principal components that best explained the vari-
ance of the data and tested these components on the
variables of malaria, vaccination, age, and site. Correla-
tions between IgG to all antigens were done by Spearman.
For PLS-DA, the analysis was performed using the log10-
transformed antibody levels of all antigen-isotype pairs at
M3 for only RTS,S vaccinees. Then, we used the PLS-DA
components to fit multivariable logistic regression models,
including also age and site. Finally, we calculated the area
under the curve (AUC) performance using the prediction
of malaria outcome obtained with the PLS-DA and calcu-
lated overfitting parameters of the model (cumulative R2)
to determine its quality. To check for areas of amino acid
similarity in antigens with CSP that might cause cross-re-
activity of RTS,S-induced antibodies, we aligned se-
quences using BLAST queries of each full-length antigen
to the CSP. Additionally, we assessed the similarity of spe-
cific peptides by aligning 25 amino acid (a.a.) sequences
overlapping by 7 a.a. against full-length CSP. We consid-
ered any hits with E value < 1 as significant, but also re-
port the hits for the default threshold E value < 10 in
Additional file 1.
Results
Baseline characteristics
We analyzed a total of 195 subjects (78 in Kintampo,
Ghana, and 117 in Manhiça, Mozambique) with samples
available at both pre-vaccination (M0) and post-vaccin-
ation (M3) [7]. RTS,S/AS01E (n = 129) and comparator
(n = 66) vaccinees were similar with regard to baseline
characteristics (age, sex, WAZ, HAZ, other vaccinations,
previous malaria, season, distance to health center, Hb
concentration), and most participants (93%) completed
the 12-month post-vaccination follow-up [7]. The me-
dian time to drop-out of the study was 113 days (range
21–276), and most were early terminations due to loss
to follow-up (7 subjects) or migration (4 subjects). A
total of 89 malaria clinical events were recorded during
the follow-up period: 60 in Kintampo (36 in RTS,S and
24 in comparators) and 29 in Manhiça (18 in RTS,S and
11 in comparators). Thirty-five clinical malaria events
(39%) were registered in the children age cohort (48% in
Kintampo, 21% in Manhiça), and the remaining in the
infant age cohort. Parasitemia of subjects who had clinical
malaria was comparable between RTS,S and comparator
vaccinees. The Kaplan-Meier median follow-up time was
365 days (IQR = 128 to 365).
P. falciparum antigens are grouped into decreasing,
unaffected, and increasing antibody responses to
RTS,S/AS01E vaccination
First, we aimed to assess the impact of RTS,S vaccin-
ation on the levels of IgG and IgM to vaccine-unrelated
P. falciparum antigens 1 month post-vaccination (M3).
We measured IgG and IgM levels (expressed as log10
MFI) (Additional file 1: Table S1) at M0 and M3 and an-
alyzed the effect of vaccination in univariable and multi-
variable models adjusting for age, site, baseline levels at
M0, and previous malaria episodes from M0 to M3. We
defined three different groups of antibodies based on the
three different patterns of antibody responses that
emerged upon RTS,S immunization, primarily based on
IgG levels (Additional file 1: Table S2 multivariable
models and Table S3 univariable models): decrease in
antibody levels (“group i” antigens, Fig. 1a); no change in
antibody levels (“group ii” antigens, Additional file 1:
Figure S1a); increase in antibody levels (“group iii” anti-
gens, Fig. 1b). IgG levels to MSP142, EXP1, and AMA1
were significantly (or borderline statistically significant)
lower in RTS,S vs comparators vaccinees at M3 (Add-
itional file 1: Table S2). In contrast, IgG levels to
EBA140, EBA175 R3–5, MSP1 Block (Bl) 2 (3D7, Well,
RO33, and MAD20 strains), MSP5, MSP6, RH2 2030,
RH4.2, RH5, and SSP2 (TRAP) were significantly higher
in RTS,S vs comparators vaccinees at M3 (Additional file 1:
Table S2) and/or vs baseline levels in RTS,S vaccinees only
(Fig. 1b). More specifically, RTS,S vaccination increased
from 1.52 to 6.55 times the M3 IgG levels against group iii
antigens compared to comparators. IgM levels remained
largely unaffected by RTS,S vaccination (Additional file 1:
Figure S1b) except for MSP142 3D7 that was significantly
higher in comparators, as was seen for IgG to this anti-
gen, and SSP2 that was significantly higher in RTS,S
vaccinees (Additional file 1: Table S3a). To sum up,
Dobaño et al. BMC Medicine          (2019) 17:157 Page 4 of 19
RTS,S vaccination differently affected the IgG levels 1
month post-vaccination, depending on the antigens.
Effect of other variables on antibody responses to P.
falciparum antigens
Next, we wanted to understand the effect of the study co-
variates on the M3 antibody levels measured, which could
help explain the three patterns of responses that we ob-
served upon vaccination. Comparing antibody levels over
time, IgGs did not change markedly from M0 to M3.
However, for some group i and ii antigens (AMA1,
EXP1, MSP2, MSP3 3D7, EBA175 R2 F2, and the preg-
nancy-related VAR2CSA DBL1–2 and DBL3–4), IgG
levels decreased with age from M0 to M3 (Fig. 1a)
probably reflecting decay of maternal antibodies. Chil-
dren had higher IgG levels than infants for most of the
antigens at M3 in adjusted models (Additional file 1:
Table S2), particularly for group ii (not affected by RTS,S)
A
B
Fig. 1 Effect of RTS,S/AS01E vaccination on IgG levels to non-RTS,S P. falciparum antigens at month 3. a Group i: Antibody levels at month 3 (M3)
were lower in RTS,S than in comparator vaccinees. b Group iii: Antibody levels were higher at month 3 in RTS,S than in comparator vaccinees.
Some representative examples are shown. Group ii antigens are illustrated in Additional file 1: Figure S1. Boxplots illustrate the medians and the
25th and 75th quartiles, whiskers display 1.5 times interquartile ranges, and diamonds show the geometric mean. Groups were compared
through t tests and p values corrected for multiple comparisons using the Holm approach. Raw p values and adjusted p values in parenthesis are
shown. log10 MFI, log10 of the median fluorescence intensity levels measured by quantitative suspension array technology
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and group iii (increased by RTS,S) antigens. At M0, IgG
levels to group i antigens were higher in infants than in
children in adjusted models, and there was a mixed
pattern for group ii and iii antigens (Additional file 1:
Table S4b). IgM levels to most antigens were signifi-
cantly higher in children than in infants at M0 and
were similar between age groups or higher in children
at M3 (Additional file 1: Tables S2 and S3).
Regarding the effect of geographical location (site), M0
IgG levels for all antigens and IgM levels for most
antigens were significantly higher in Kintampo than in
Manhiça in adjusted models (Additional file 1: Table S4b),
reflecting the higher MTI in Kintampo. However, many
antibodies were not significantly different at M3 by site in
adjusted models, and an inverse pattern was seen for IgG
to many group iii antigens, MSP3 and LSA1, whereby
levels were higher in Manhiça than in Kintampo
(Additional file 1: Table S2).
Higher baseline Hb concentrations and WAZ (and
HAZ to a lesser extent) were significantly associated with
lower M0 IgM levels to most antigens in adjusted models,
and some similar significant associations were found for
IgG (Additional file 1: Table S4b). Sex had no significant
associations with baseline IgG or IgM levels. The stron-
gest and most consistent associations were for previous
episodes of clinical malaria and higher M0 antibody levels
(to the homologous antigen), both predicting higher M3
antibody levels (Additional file 1: Table S4). The magni-
tude of the associations, particularly for prior malaria epi-
sodes, was higher with greater significance for IgG than
for IgM. Group i and ii antigens (MSP142, EXP1,
MSP2) were more affected by previous malaria.
Overall, these results suggest that antigens from groups
i and ii are more immunogenic and reflect better malaria
exposure than antigens from group iii.
Correlations of RTS,S and non-vaccine-related antibody
responses
We performed PCA of all M3 antibody responses, in-
cluding IgG and IgM levels to RTS,S antigens (NANP,
C-terminus, and CSP full length [7]), to reduce the
dimensionality of the data and get insights into the rela-
tionship between vaccine and non-vaccine antibody
responses. Study participants clustered by vaccine group
(Fig. 2a) and principal component 2 (PC2 or dimension 2)
separated both clusters. The 10 antibody responses con-
tributing more to PC2 were, as expected, IgG against the
three CSP constructs, IgM to CSP full length, but also
group iii antigens: RH4.2 (that was highly correlated with
CSP), four MSP1 Bl2 constructs, and EBA140 (Fig. 2a, b).
Correlations among IgG responses to non-RTS,S anti-
gens of groups i, ii, and iii, in addition to RTS,S vaccine
antigens, in RTS,S vaccinees, are depicted in Fig. 3.
Three main patterns were observed: (1) most group iii
antigens and CSPs significantly correlated among them-
selves, although to varying degrees (rho between 0.25
and 1); (2) MSP142, AMA1, MSP3 3D7, and VAR2CSA
(DBL1–2 and DBL3–4) correlated negatively (rho be-
tween − 0.25 and 0) with CSPs, and together with MSP2
full-length Dd2 correlated negatively with MSP1 Bl2
Well (rho between − 0.5 and 0), and VAR2CSA (DBL1–
2 and DBL3–4), MSP3 3D7, and AMA1 correlated nega-
tively with most group iii antigens and some group ii
antigens (rho between − 0.25 and 0); and (3) some group
ii and all group i and iii antigens correlated positively
among themselves (mainly with rho > 0.25) (Fig. 3). In
addition, group ii antigen RH4.9 correlated negatively
with CSP and some antigens of all three groups.
To assess whether antibody responses correlating with
CSP could be an artifact of cross-reactive CSP antibodies,
we aligned the P. falciparum 3D7 strain ortholog of each
protein in this study with CSP to check for regions of local
a.a. similarity. Among all proteins, including the GST tag,
only SSP2 showed significant primary structure with E
value < 1 for full-length queries (a.a. 249–286, % identity =
37.8, E value = 1.44E−05), aligning with the thrombospon-
din type 1 domain-containing CSP a.a. 330–374. At the
peptide level (7 a.a. overlapping 25mers), two sequential
SSP2 fragments had significant similarity corresponding
to a.a. 235–259 (% identity = 90.9, E value = 0.002) and a.a.
253–277 (% identity = 66.7, E value = 0.17), the region of
SSP2 containing a C-terminal thrombospondin type 1 do-
main. Additional hits using the default E value threshold
of 10 are described in Additional file 1.
Antibodies to group i and ii antigens had no effect or
were associated with increased risk of clinical malaria
We next wanted to decipher the role of the antibody re-
sponses measured in protection against clinical malaria.
Having higher baseline IgM to most P. falciparum anti-
gens, and higher baseline IgG to half of the antigens,
was associated with occurrence of clinical malaria during
the 12-month follow-up period after M3.5, as illustrated
in Fig. 4 for IgG. In the univariable analysis, M3 anti-
bodies to group i antigens and some group ii antigens
that are considered markers of exposure (including ma-
ternal exposure) were higher in malaria cases than in
controls (Fig. 4); stratified by age, this was more signifi-
cant in children (Additional file 1: Figure S3). IgG levels
to the above antigens that were significantly higher in in-
fants than in children with malaria at baseline and in
comparators were presumably derived from the mother
(Additional file 1: Figure S3). In the multivariable ana-
lysis, these risk associations disappeared except for IgG
to group i antigen AMA1 FVO (Table 1) and IgM to
RH2 (2030) (OR = 3.66 [1.44; 10.03], p = 0.008).
Analysis of the change in IgG levels between M0 and M3
(log10 FC) showed that there were either no significant
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effects of log10 FC on malaria risk or, if there were, IgG
levels declined from M0 to M3, and the decrease was lower
in non-malaria controls than in malaria cases (Fig. 4). The
drop in antibodies from M0 to M3, more pronounced in
infants, and the lower decrease in protected subjects, could
be due to more production and/or less antibody decay from
M0 to M3. In fact, age-stratified analyses (Fig. 5 and
Additional file 1: Figure S3) showed that malaria-protected
children had an increase of IgG against EXP1 and MSP2
from M0 to M3, whereas children with malaria cases had a
decrease and, therefore, significantly higher log10 FC in pro-
tected children. In multivariable analysis, IgG log10 FC was
associated with malaria protection for EXP1 (OR = 0.6
[0.38; 0.91], p = 0.02), MSP2 Dd2 (OR = 0.54 [0.32; 0.87],
p = 0.02), and MSP2 CH150 (OR = 0.58 [0.37; 0.88],
p = 0.01, also for IgM).
Antibodies to group iii antigens were associated with
reduced risk of clinical malaria
In contrast, higher M3 IgG levels to three group iii anti-
gens, SSP2 and MSP1 Bl2 (strains RO33 and Well,
borderline for 3D7), were significantly associated with
reduced risk of clinical malaria (Table 1). In these multi-
variable analyses, RTS,S vaccination, children age cohort,
Manhiça site, low baseline antibody levels, and high
WAZ were associated (statistically significantly or not)
with lower risk of malaria (Table 1). Sex, prior malaria
episodes, season, HAZ, or Hb concentrations did not
significantly contribute to the models for any antigen. In
addition, non-malaria controls had significantly higher
log10 FC than malaria cases (Fig. 4), unlike the pattern
seen for some group i and ii antigens. Stratifying by age
group and site, the protective association was seen only
for children and mainly in samples from Kintampo
(Fig. 5b). In the multivariable analysis, an association
with protection between higher IgG log10 FC and malaria
was significant for MSP5 (OR = 0.62 [0.41; 0.91], p = 0.02)
in addition to SSP2 and MSP1 Bl2 RO33 and Well strains,
for which M3 levels were also significantly associated with
protection (Table 1), and additionally for MSP1 Bl2
Mad20 (OR = 0.3 [0.09; 0.88], p = 0.03).
Multimarker analyses of antibody levels and malaria
protection
To perform multimarker analysis accounting for co-
linearity in antibody responses, we performed PLS-DA
of antibodies at M3 among RTS,S vaccinees, with mal-
aria as a response variable (Fig. 6a, b), and identified two
A
B
Fig. 2 Relationship among antibody responses to RTS,S and non-RTS,S antigens after RTS,S/AS01E vaccination. a Principal component analysis
(PCA) plots of individuals clustered by vaccine type. The first three principal components (Dim 1, Dim 2, and Dim 3) that explained the highest
percentage of the variance of the IgG and IgM data at month 3 (percentage in parenthesis) were chosen for representation. b Contribution of
the top 10 variables to the PCA Dim 2. The red dashed line indicates the expected average contribution. Any variable with a contribution above
this cutoff can be considered as important in contributing to the component
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components associated with the outcome. Interestingly,
the loadings of component 1 (Fig. 6b) showed a pattern
in which roughly all group i and ii antigens and almost
half of group iii antigens were associated with increased
malaria risk. IgG levels to the other half of group iii
antigens (SSP2, MSP5, EBA140, MSP1 Bl2 [RO33, Well,
3D7], RH4.2) and CSP (C-terminus, NANP, and full
length) were associated with protection, whereas almost
all IgM levels to the same antigens were associated with
increased risk. In component 2, there was a mixed pat-
tern for groups i and ii antigens, while IgG and IgM to
exactly the same group iii antigens as component 1 were
associated with protection. In a multivariable logistic
model including these two PLS-DA components and
adjusted by age and site, the PLS-DA components were
independently associated with malaria (component 1:
OR = 1.26 [1.09; 1.48], p = 0.002 and component 2:
OR = 1.31 [1.06; 1.66], p = 0.016), while age was not
(OR = 1.22 [0.38; 3.93], p = 0.73) and site was border-
line (OR = 0.33 [0.11; 1.01], p = 0.05). The predictive abil-
ity of the model was moderate (33 out of 54 malaria cases
and 64 out of 75 controls correctly predicted) with an
AUC of 0.732 and a cumulative R2 of 0.397.
A schematic summary of the characteristics of anti-
body responses to group i vs iii antigens is shown in
Fig. 7. Antigens to which there were more maternally
derived antibodies at M0 and increased with previous
malaria at M3 (and by M0 levels), and for which levels
were higher in Kintampo than in Manhiça (group i), were
the ones that did not increase with RTS,S vaccination at
M3, and vice versa. Table 2 shows a summary of the ana-
lyses of correlates with malaria risk and protection.
Discussion
Immunization with a partially effective PE malaria vac-
cine, RTS,S/AS01E, may affect the acquisition of IgG
and IgM responses to multiple PE and BS P. falciparum
antigens upon natural microbial exposure in young Afri-
can hosts, some of whom have maternal IgGs. Our re-
sults reveal an association between these antibody levels
and protection against clinical malaria, in two areas of
different endemicity. Data from a phase 3 clinical trial
showed that RTS,S vaccination can alter NAI antibodies
to P. falciparum in two different ways: by decreasing
antibody levels (“group i” antigens), as seen in prior
phase 2b trials [12, 13, 24], or by increasing IgG levels
(“group iii” antigens), which to our knowledge has not
been reported before, likely due to the limitations of pre-
vious studies in their breadth of antibody screen and
time points available for study. This study had the add-
itional advantage of being able to draw on the associ-
ation between antibodies to NAI antigenic targets and
protection from, or risk of, clinical malaria measured
prospective in a controlled multicenter trial.
On the one hand, RTS,S vaccination decreases exposure
to the parasite by providing protection against malaria
Fig. 3 Correlation among IgG responses in RTS,S vaccinees. Colors indicate Spearman coefficients (rho). p values: *< 0.05, **< 0.01, ***< 0.001
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infection and this would be reflected in the reduction of
antibody levels to P. falciparum antigens that are primarily
markers of microbial exposure, even if functional antibody
activity exists. This effect would be more distinct with
time, as seen in prior phase 2b studies by Campo et al. 6
months after vaccination (M8.5 visit), particularly in youn-
ger children [12, 13]. In our phase 3 study, group i anti-
gens that are considered and used as markers of MTI in
seroepidemiological surveys [15] showed this pattern,
specifically MSP142 and AMA1. Notably, as early as 1
month post-vaccination (M3), there were some signifi-
cant differences in antibody levels as a result of reduced
P. falciparum BS exposure associated with vaccine effi-
cacy. Antibodies to MSP142, in particular, appear to be
very fast and sensitive sensors to detect changes in para-
site exposure. We predict that with time, antibody levels
A
B
Fig. 4 Association between IgG responses to non-RTS,S antigens and malaria protection. a Antigen groups i and ii. b Antigen group iii. Levels of
IgG and change from pre- (M0) to post-vaccination (M3). Some representative examples of the distinct patterns observed in each group are
shown. Boxplots illustrate the medians and the 25th and 75th quartiles, whiskers display 1.5 times interquartile ranges, and diamonds show the
geometric mean. Groups were compared through t tests and p values corrected for multiple comparisons using the Holm approach are shown.
M malaria, NM no malaria, log10 MFI log10 of the median fluorescence intensity (MFI) levels measured by quantitative suspension array
technology, M3-M0 change between M0 and M3 antibody levels expressed as log10 MFI
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to most group ii antigens would also be reduced as a result
of RTS,S vaccination, similar to the Campo et al. studies.
Antibodies to group i and ii antigens behave as markers of
exposure based on multiple criteria: (a) they are signifi-
cantly higher in Kintampo (higher MTI) than in Manhiça
(lower MTI), (b) increase significantly if the subject had
prior malaria episodes, (c) M3 levels strongly correlate
with M0 levels, and (d) point toward an increased malaria
risk (AMA1). Furthermore, IgG levels for many of those
antigens are elevated at baseline, higher in infants than in
children, and significantly decay from M0 to M3, indi-
cating a predominantly maternal origin. Transplacental
A
B
Fig. 5 Association between IgG levels to non-RTS,S antigens and malaria protection stratified by age and site. a Antigen groups i and ii. b Antigen
group iii. Change from pre- (M0) to post-vaccination (M3) antibody levels. Some representative examples are shown. Boxplots illustrate the medians
and the 25th and 75th quartiles, whiskers display 1.5 times interquartile ranges, and diamonds show the geometric mean. Groups were compared
through t tests and p values corrected for multiple comparisons using the Holm approach are shown. M malaria, NM no malaria, M3-M0 change
between M0 and M3 antibody levels expressed as log10 of the median fluorescence intensity (MFI) measured by quantitative suspension
array technology
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antibodies at birth are also a reflection of MTI in the
community, and higher levels at baseline are associated
with prospective malaria risk. IgG to some antigens like
AMA1 and VAR2CSA DBL1–2 and DBL3–4 appear to
be longer-lived maternal antibodies, as they remain
higher in infants than in children also at M3.
On the other hand, our data also show that vaccination
with RTS,S can result in an increase in antibody levels to
other antigens (group iii) with respect to comparators and
baseline. Stratified by age, the effect of increased antibody
levels at M3 by RTS,S (not comparator) vaccination is
manifested in both infants and children but appears more
pronounced in children. This could be because children
have more exposure cumulatively and no maternal IgG
remaining at M3 that could interfere with the build-up of
their own antibodies. It could also be that children are
able to produce stronger responses just because of intrin-
sic age-related particularities of the immune system, such
as maturation of T-dependent B cell responses [25]. Inter-
estingly, upon RTS,S vaccination, IgG levels to group iii
antigens increased in both sites, Manhiça and Kintampo;
however, Manhiça had a greater increase post-vaccination
than Kintampo, perhaps representing complex interac-
tions between host immune response and levels of para-
site exposure. Remarkably, the M0 to M3 antibody
kinetics and the analysis of factors affecting the Ig levels
suggest that group iii antigens are weaker markers of
exposure than group i and ii antigens and that infants are
not born with high IgG to them. It could be that anti-
bodies to these antigens might be transferred less transpla-
centally (due to antigen-driven polarization of subclasses
or glycoprofiles affecting binding to FcRn) or that mothers
have lower levels. Thus, adults could have lower IgG levels
to group iii antigens than children, i.e., an age pattern such
that antibodies increase in early infancy and childhood
but at some point decrease and are lower in adults, con-
trary to group i antigens. For some antigens like EBA140,
this is consistent with prior analyses of RNA expression in
parasites that decreased with age [26]. The different age
pattern of group iii antibodies (e.g., EBA140) points to
A
B
Fig. 6 Multimarker analysis of antibody responses to RTS,S and non-RTS,S antigens after vaccination and malaria protection. a Partial least squares
discriminant analysis (PLS-DA) scatter-plot with the two PLS-DA components that best enable discrimination between malaria cases (blue) and
non-malaria controls (pink). b Loadings of antibody response for each PLS-DA component colored by antigen group: group i (light blue), group ii
(dark purple), group iii plus vaccine antigens (yellow)
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different roles in anti-disease vs anti-parasite immunity,
which may be acting at different phases of NAI acquisi-
tion. Therefore, it could be that the antibody “enhance-
ment” seen with RTS,S for group iii antigens may be
related mostly to the absence/low levels of maternally
derived IgGs to these antigens such that host responses
are not interfered with, in contrast to group i and ii anti-
gens. Overall, there seems to be an inverse relationship
between group i + ii (“exposure”) vs group iii antigens (see
opposite patterns in Fig. 7 and Additional file 1: Table S2
and Figure S2). Interestingly, antibody levels are heteroge-
neous within antigen groups, as different behaviors are ob-
served upon close examination that imply that the
determinants and patterns of antibody responses to each
individual antigen are more complex and diverse than
these three categories. For example, when IgG to group i
and ii antigens are stratified by age, IgG responses to
EXP1 and MSP2 in RTS,S-vaccinated children (who do
not have maternal antibodies at M3) resemble those of
group iii antigens.
How could a vaccine that reduces exposure to the
parasite be associated with an increase in antibody
levels? This could be related to the fact that RTS,S may
not result in sterile immunity, particularly in the longer
term. Instead, it appears to be a partially effective or
“leaky” PE vaccine. To explain the differences in dur-
ation of vaccine efficacy between two cohorts subject to
diverse MTI in the Mozambican phase 2b trial, we hy-
pothesized that partial protection afforded by RTS,S/
AS0 may stimulate protective antibodies to certain asex-
ual BS target antigens, through a reduction in merozoite
release from the liver, leading to attenuated BS parasit-
emia. As CSP-specific highly protective immunity decays
in the short term [27–30], incoming infections would be
partially controlled resulting in subpatent low antigen
doses that elicit enhanced antibody production to certain
antigens. This would be reflected in accelerated acquisi-
tion of BS protective immunity [10, 12, 29]. As this is an
exposure-dependent mechanism, the outcome will differ
depending on the force of infection to which subjects
are exposed, i.e., MTI- and age-dependence. Therefore, a
certain MTI window (enough but not too much) may
maximize benefits of RTS,S vaccination and baseline fac-
tors (e.g., frequency/intensity of parasite exposure, pres-
ence of maternal antibodies) may modulate non-RTS,S
antigen responses affected by the vaccine. This would
imply that the potential positive impact of immunization
with RTS,S or other leaky vaccines may not be apparent
in sites with too low MTI and that it might be lost in
sites with too high MTI, which may overwhelm the ini-
tial required protective effect in the liver stage. It is re-
markable that this antibody enhancement phenomenon
can occur in the short 3-month interval of our study
(during vaccination and 1month post-vaccination). The
concept of immunologically favorable impact of low-
level infections is not new, as a similar explanation was
proposed for the prolonged protective effect of intermit-
tent preventive treatment in infants with sulfadoxine-
pyrimethamine (IPTi-SP) in Tanzania upon interruption
of treatment [31]. Thus, induction of effective and sus-
tained immunity against malaria by IPTi (or RTS,S)
could be due to the generation of low-dose blood-stage
inocula and attenuated infections [32], and this could
translate into higher antibody responses [33]. Addition-
ally, insecticide-treated bednet use can also enhance
antibodies [34] and ultra-low dose of BS infection can
protect [11], although residual antimalarial concentra-
tion before challenge compromised these results, and
protection was not thought to be antibody-mediated.
Furthermore, not only BS but also PE antibodies like
anti-SSP2 IgG and IgM increased. Conceivable, this
could be an independent mechanism whereby RTS,S-
induced CSP antibodies [7] recognizing parasites may
increase phagocytocis of sporozoites which leads to
presentation of other PE antigens to the immune sys-
tem and consequent antibody responses. The fact that
RTS,S affects non-vaccine antibody responses would
suggest an association between antibody levels to CSP
and group iii antigens, as shown in the PCA and correl-
ation analyses here. At least at the level of primary
structure, there is little evidence that RTS,S-induced
CSP antibodies cross-react with group iii antigens with
the alignment strategy used here. This does not
Fig. 7 Summary chart of antibody responses to group i and group
iii antigens
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preclude the possibility of tertiary structure or other
undetected similarities between any of the antigens
tested with CSP, but does suggest that the group iii an-
tigens identified in this analysis represent targets of
specific antibodies affected by RTS,S vaccination.
What is the immunological relevance of RTS,S-medi-
ated changes in non-vaccine antibodies on malaria pro-
tective immunity? Antibodies to group i and ii antigens
were generally associated with increased malaria risk,
consistent with their role as markers for identifying in-
dividuals under the highest attack rates. There is little
dispute that antibodies to exposure antigens such as
AMA1 can protect against malaria, particularly allele-
specific infection [35], but these effects are often con-
founded in immunoepidemiological studies by the
strong effect of prior exposure on both antibodies and
future risk of repeated infection [36]. In contrast, anti-
bodies to group iii antigens seem to have a clearer asso-
ciation with NAI in our study. Among group iii
antigens, the most consistent associations between M3
antibody levels and immunity were for MSP1 Bl2
[RO33, Well, 3D7], MSP5, EBA140, RH4.2, and SSP2
antigens. Antibody responses to MSP1 Bl2 [37], MSP5
[38, 39], EBA140 [40], and RH4.2 [41, 42] BS antigens
have been previously associated with protection against
malaria, and SSP2 (TRAP) is the target of other leading
subunit PE vaccine candidates [43]. Functionally, anti-
bodies against erythrocyte binding antigens, including
EBA140 [44], and against the reticulocyte binding pro-
tein-like homolog family, particularly RH4 and RH5
[45], have shown in vitro inhibition of erythrocyte inva-
sion. These parasite proteins play critical roles as
ligands for host erythrocytes and the process of mero-
zoite invasion. It follows that RTS,S enhancement of
such antibodies could provide an additional layer of
protective immunity on the back end of an infection.
The functional relevance of MSP5 antibodies is less clear,
although antibodies to MSP5 orthologues have been
Table 2 Summary table of associations between IgG responses and malaria protection. Dark purple represents association with
protection and light blue with risk
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protective in animal models [46, 47]. Interestingly, MSP5
has high levels of expression in P. falciparum sporozoites
(PlasmoDB.org; [48]), and MSP5 antibodies correlate with
the PE sterile protection observed in humans immunized
with irradiated sporozoites (Campo et al., in preparation),
perhaps hinting at a multistage function of MSP5 anti-
bodies. Under certain circumstances (e.g., in children with
low baseline Ig), antibody responses to EXP1 and MSP2
and other antigens may also have a role in protection.
What is the net impact of the interaction between
RTS,S immunization and NAI on overall protection
against malaria? On one hand, there is a potential
negative effect whereby RTS,S vaccination, by provid-
ing protection against malaria infection, might reduce
NAI that would normally be induced by repeated in-
fections. This could render vaccinated children more
susceptible when the vaccine effect wanes [49] if such
antibodies were mediators of NAI, and potentially
lead to malaria “rebound” [50]. However, it appears
that antibodies that decrease following RTS,S vaccin-
ation are mostly markers of exposure that reflect vac-
cine efficacy [12, 13, 24]; thus, this may not be a
concern. On the other hand, there is a potential posi-
tive impact whereby NAI could improve overall vac-
cine efficacy in the capacity of RTS,S to protect
against malaria, combining the effect of experimen-
tally elicited and NAI-dependent immunity, and this
may be age- and/or exposure-dependent. Malaria pre-
vention in early life when the infant is at highest risk
of the negative effects of infection is thought to con-
tribute to an overall lower risk of severe morbidity
and thus mortality in childhood [51]. Varying endem-
icity may differentially influence the long-term mor-
bidity and mortality risk so that the benefits of RTS,S
vaccination may be maximized in moderate MTI
settings. In the pediatric field trials of RTS,S, there
was evidence of different vaccine efficacies depending
on malaria surveillance system and MTI [29], al-
though in the phase 3 trial differences due to MTI
were only significant in children when administered
with a vaccine booster dose [49]. The long-term im-
pact of the interaction between RTS,S vaccination and
NAI on duration of vaccine efficacy and overall
protection against malaria will be investigated in fol-
low-up studies including the subsequent trial visits at
M20, M21, and M32 till study end. We speculate that
antibodies altered by RTS,S vaccination will affect
the longevity of protective immunity in an age- and
MTI-dependent manner.
Importantly, our study provides evidence for a positive
effect of RTS,S on antibody responses to certain antigens
that are associated with protection. Since multivariable
logistic regression models in which IgGs to MSP1 Bl2,
MSP5, and SSP2 (that are increased by vaccination) were
associated with protection were adjusted by RTS,S vac-
cination, there is an additional protective effect of these
antibodies on top of the protection afforded by the RTS,
S vaccine. We postulate that these responses are contrib-
uting to the RTS,S-induced malaria protection and that
these antigens could improve efficacy in a future
multivalent next-generation vaccine. Such formula-
tions raise the possibility of saturation of the immune
system, having to react simultaneously to multiple an-
tigens. However, there are vaccines given through the
expanded program of immunization (EPI) that contain
more than 3 antigens and are able to induce adequate
immune responses. Moreover, it is envisaged that in
the pilot implementation starting 2019 in three Afri-
can countries, RTS,S will not be administered to in-
fants as part of the EPI but to children age 5–17
months; thus, immune saturation may not represent a
significant limitation.
The study design has some limitations that could be
addressed in follow-up studies including more sites and
larger sample size. In Kintampo, all children who fulfilled
the inclusion criteria, most of whom had malaria, were an-
alyzed. Whereas in Manhiça, a case-control design was
needed because there were fewer cases; a cohort design
would have required increasing the number of samples
substantially to have power to detect association with pro-
tection. In Manhiça, there was also an age imbalance, as
most cases were in infants. In addition, the phase 3 trial
design did not allow for collection of genetics data from
the volunteers. Therefore, host genetics-based differences
in the immune responses to vaccination between the
two African populations, including hemoglobinopathies
such as the sickle cell trait, could not be assessed here.
Despite this and having many antigens and multiple
comparisons, patterns emerged that were consistent
and biologically plausible.
Conclusion
Baseline characteristics related to age and exposure ap-
pear to modulate the nature and magnitude of antibody
responses to distinct sets of P. falciparum antigens in-
duced by the interaction between vaccination and NAI.
Importantly, antibodies to certain antigens which may
be targets of protective NAI may be enhanced by RTS,
S/AS01E vaccination, contributing to vaccine efficacy.
These antigens could potentially be candidates of
multivalent next-generation RTS,S formulations to im-
prove vaccine efficacy as additive (or synergistic) re-
sponses with CSP may occur. We postulate that
antibodies affected by RTS,S/AS01E vaccination at peak
response will contribute to the duration of protection.
We plan to test this hypothesis in the extended follow-
up of the phase 3 trial.
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